摘要
阿尔茨海默病(AD)是一种老年期的神经退行性疾病,早期干预是目前延缓该病进展的唯一可靠手段。该文汇总并分析近年来各类AD生物标志物研究的代表性文献,分类评述了各类脑脊液(GSF)标志物对AD诊断及鉴别诊断的效能。其中CSF Aβ42、Aβ42/Aβ40、tau蛋白、Aβ42/p-tau、生长相关蛋白43、突触相关蛋白25、神经颗粒素、人视锥样蛋白1等对AD诊断、鉴别诊断均具有较大价值。CSF标志物可用于AD诊断及鉴别诊断。实验室应根据自身条件,针对AD选择适宜的CSF标志物。
Alzheimer disease(AD)is a neurodegenerative disease in the elderly.Early intervention is the only reliable means to delay the progress of the disease.Referring to the diagnostic criteria of AD,this paper summarizes and analyzes the representative literatures of various AD biomarkers derived from cerebrospinal fluid in recent years,and reviews the efficacy of various cerebrospinal fluid biomarkers in the diagnosis and differential diagnosis of AD.Results show that CSF Aβ42,Aβ42/Aβ40,T-tau,p-tau,Aβ42/p-tau,growth-associated protein 43,synaptosomal-associated protein 25,neurogranin and visinin-like protein-1 are of great value in the diagnosis and differential diagnosis of AD.The above CSF biomarkers can be used in the diagnosis and differential diagnosis of AD.The laboratory should select appropriate AD CSF biomarkers according to its own conditions in daily laboratory works.
作者
张晓敏
崔雨婷
张晶晶
王怡斐
王培昌
Zhang Xiaomin;Cui Yuting;Zhang Jingjing;Wang Yifei;Wang Peichang(Clinical Laboratory of Xuanwu Hospital,Capital Medical University,Beijing 100053,China;Department of Clinical Laboratory Diagnostics,Capital Medical University,Beijing 100069,China)
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2022年第1期8-13,共6页
Chinese Journal of Laboratory Medicine
基金
国家自然科学基金(82030064)
2021年度“扬帆”计划重点医学专业(ZYLX202114)
北京市临床重点专科(建设项目)。